MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial

Publication date: Available online 11 March 2020Source: The Lancet HaematologyAuthor(s): Marc S Raab, Monika Engelhardt, Antje Blank, Hartmut Goldschmidt, Hermine Agis, Igor W Blau, Hermann Einsele, Barbara Ferstl, Natalie Schub, Christoph Röllig, Katja Weisel, Mark Winderlich, Janine Griese, Stefan Härtle, Johannes Weirather, Tiantom Jarutat, Christian Peschel, Manik Chatterjee

Source: The Lancet Haematology - March 12, 2020 Category: Hematology Source Type: research